2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer

EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study

Pdf Summary

The study conducted by S. Verma and colleagues at the Verspeeten Family Cancer Centre, Western University, examines the effectiveness and safety of neoadjuvant immuno-chemotherapy in the treatment of resectable non-small cell lung cancer (NSCLC). This retrospective analysis assesses patients who received a regimen of nivolumab combined with chemotherapy before surgery, focusing on those with tumor size ≥4 cm or node-positive disease, but not involving N3 nodes or T4N2. Data is collected on various metrics including baseline characteristics, imaging responses, pathological responses, treatment specifics, and toxicity levels from September 2022 to March 2024.<br /><br />Background context highlights the significance of neoadjuvant chemo-immunotherapy as the new standard in early-stage resectable NSCLC, with evidence from the CheckMate 816 trial showing improved pathological complete response rates and three-year event-free survival outcomes. The present study seeks to provide real-world data to complement these findings.<br /><br />Results from the paper indicate that neoadjuvant nivolumab and chemotherapy were associated with high pathological complete response (pCR) rates, with 33% of patients achieving this outcome. Objective response rate stood at 78%, with a complete response in 11% and partial response in 67% of patients. The majority proceeded to surgery, with 83% undergoing surgical resection and 93% achieving R0 resection status. There were instances of progressive disease and significant toxicities, emphasizing a need for careful patient selection.<br /><br />The study points out its limitations, notably being retrospective and single-centered, lacking data on survival and quality of life outcomes. It stresses the importance of identifying biomarkers to predict treatment response and toxicity levels more effectively, allowing for better patient selection to optimize outcomes.

Asset Subtitle

Saurav Verma

Meta Tag

Speaker Saurav Verma

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant immuno-chemotherapy

non-small cell lung cancer

NSCLC

nivolumab

pathological complete response

CheckMate 816 trial

retrospective analysis

tumor size

treatment toxicity

biomarkers